Participated · Series I · Sep 2023

Databricks operates a cloud data platform and AI products, with its core cloud data warehouse generating $1.5 billion of its annualized run-rate revenue and growing 100% year-over-year. The company reported a $7 billion annualized run-rate revenue figure while growing at roughly 80% and being cash-flow positive. Databricks launched Lakebase in June 2025, which has reached a $100 million revenue run-rate, and its AI chatbot tool Genie is described as highly popular. The company maintains a roughly 100-person AI research team and faces multi-billion-dollar cloud commitments with major hyperscalers. Databricks has been active on the M&A front, acquiring companies including Electric (PGlite) and AI cybersecurity firm Panther, and it says it plans to continue investing in AI and acquisitions while remaining open to a future IPO.

Participated · Series D · May 2021

Klaviyo is an e-commerce marketing automation platform that integrates with platforms like Octane AI and Recharge to automate email and SMS campaigns. Users can set up triggers for abandoned carts, product recommendations and other messages, leveraging templates and predictive analytics. Founded in 2012 and based in Boston, Klaviyo has over 1,000 employees and more than 100,000 paying customers, including Unilever, Dermalogica, Solo Stove and Citizen Watches. To date the company has raised around $775 million and was valued at $9.5 billion as of May 2021 by investors including Sands Capital, Counterpoint Global, Accel and Summit Partners. Klaviyo faces competition from Sendlane, Sendinblue and Cordial but has grown via a customer-first, product-led approach. The company is expanding its partnership with Shopify to accelerate adoption among Shopify merchants and gain early access to in-development Shopify features. Klaviyo builds a next-generation email marketing platform that helps retailers and businesses execute "owned marketing" such as email rather than relying on platform channels. The company experienced rapid customer growth as retailers moved online during and after COVID and now serves over 70,000 paying customers in more than 120 countries. Klaviyo says its customer base doubled over the past 12 months and showed a more than 110% increase from 2019. The company is headquartered in Boston and plans to grow headcount from about 800 to 1,300 this year. Financially, Klaviyo recently raised a $320M Series D at a $9.5B valuation, bringing total capital raised to $675M after a $200M Series C six months earlier. Klaviyo is a marketing automation and customer data platform that combines customer data, message customization, and machine learning to deliver contextual customer experiences. The company positions itself as a hybrid customer data and marketing platform that lets businesses retain and use their own customer data rather than ceding it to large intermediaries. Klaviyo reports about 50,000 customers in 125 countries, with customer count doubling year over year, and has roughly 500 employees. Leadership plans to double headcount in the next year and cites diversity and an inclusive culture as strategic priorities. With the new funding, Klaviyo intends to accelerate product development, build out the platform, and enter new markets. The company has substantial runway following recent financings to pursue those growth plans. Klaviyo provides a data-driven marketing and automation platform that stores a complete view of each end customer and offers flexible, real-time segmentation and automatic revenue attribution. The platform powers highly targeted email and advertising campaigns without forcing a tradeoff between advanced functionality and ease of use. Klaviyo says customers on average grow revenues 29% more in the first six months after switching to its platform, and today more than 12,000 brands—including Bonobos, CustomInk, Colourpop, Steve Madden and Untuckit—use the product. The company emphasizes fast time-to-revenue and lower time and cost compared with traditional enterprise approaches. Klaviyo plans to use new funding to hire hundreds of engineers, build a corporate development team and expand operations predominantly in its Boston headquarters. The company describes itself as fast-growing and profitable. Klaviyo is an intelligent platform for ecommerce email campaigns that analyzes disparate and often real-time data points about individual customers and prospects to automate personalized communications. The company was founded in 2012 by Andrew Bialecki and Ed Hallen and is based in Boston, MA. Klaviyo's system is used at thousands of ecommerce companies to maximize return on email campaigns. The company raised $1.5M in funding to support its growth. Backers include Accomplice and angels David Cancel, Elias Torres and TJ Mahoney. Klaviyo intends to use the funds to accelerate development and sales/marketing efforts.

Participated · Equity · May 2021

Caris Life Sciences is a next-generation AI TechBio company and precision medicine pioneer that provides comprehensive molecular profiling through Whole Exome and Whole Transcriptome Sequencing. The company launched MI Cancer Seek after receiving FDA approval; it is the first and only simultaneous WES/WTS-based assay with FDA-approved CDx indications for molecular profiling of solid tumors in adult and pediatric patients. In 2024 Caris commercially launched Caris Assure, a minimally invasive, blood-based assay using a circulating Nucleic Acid Sequencing (cNAS) approach to analyze cell-free DNA and RNA as well as genomic DNA and mRNA from white blood cells to distinguish somatic tumor, incidental clonal hematopoiesis and incidental germline variants. Caris combines sequencing power, big data and AI/machine learning to build a large-scale, multimodal database and computing capability to analyze the molecular complexity of disease. The company says it will use its platform to deliver next-generation precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development and to bring its science and technologies to more patients. Financially, Caris closed a $168 million growth capital round and has raised $1.86 billion in capital since 2018. Caris Life Sciences develops comprehensive molecular profiling that analyzes DNA (whole exome sequencing), RNA (whole transcriptome sequencing), and protein biomarkers to reveal a patient’s molecular blueprint for selecting therapies. The company applies sophisticated AI and machine learning to identify proprietary signatures that classify cancer at the molecular level and predict patient response. Caris maintains a molecular database of over 455,000 tumor profiles, including more than 350,000 profiles with matched molecular data and clinical outcomes. Founded in 2008, the company positions itself as a leading innovator in precision medicine. Caris plans to use new capital to repay outstanding debt, enhance its precision medicine platform, and for general corporate purposes. Since 2018 the company has raised approximately $1.7 billion in capital. Caris Life Sciences provides molecular profiling services that assess DNA, RNA and proteins to create a molecular blueprint that supports personalized cancer treatment decisions. The company combines its service offering, Caris Molecular Intelligence®, with its proprietary AI analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. Caris couples these molecular data with mature clinical outcomes on thousands of patients to generate insights for patients, physicians, payers and biopharmaceutical organizations. The company is headquartered in Irving, Texas and has offices in Phoenix, Denver, New York and Basel, Switzerland, providing services across the U.S., Europe, Asia and other international markets. David D. Halbert leads the company as Chairman and CEO. The business emphasizes integrating molecular science and artificial intelligence to advance precision medicine. Caris Life Sciences develops molecular profiling and analytics to guide precision oncology decisions, offering whole exome and whole transcriptome sequencing and proteome analysis. Its product suite includes MI Exome™ and MI Transcriptome™ sequencing, Caris MAI™ (Molecular Artificial Intelligence) and the DEAN™ analytics engine. Caris Pharmatech provides Just-In-Time clinical trial solutions and a network of over 200 research-ready oncology sites to speed site activation and patient enrollment. Headquartered in Irving, Texas, the company also has offices in Phoenix, Denver, New York and Basel and serves markets in the U.S., Europe, Asia and other international regions. The company will use new capital to fund continued growth in precision medicine, accelerate product development and pursue initiatives in the clinical trial and biopharmaceutical markets. Caris is led by Chairman and CEO David D. Halbert. Caris Life Sciences is an Irving, Texas-based provider of molecular science focused on precision medicine through molecular profiling of DNA, RNA and proteins. The company advances a suite of offerings including Caris Molecular Intelligence®, the ADAPT Biotargeting System™, and the DEAN™ AI analytics engine that together support its Next Generation Profiling™. Next Generation Profiling™ aims to analyze the whole exome, whole transcriptome and complete cancer proteome and couple that molecular data with mature clinical outcomes to deliver more precise treatment recommendations. Caris offers services throughout the U.S., Europe, Asia and other international markets. Led by Chairman and CEO David D. Halbert, the company plans to continue development of Next Generation Profiling™ and expand commercial, clinical and R&D laboratory capacity. In January 2018 it raised $150M in funding provided as senior secured debt and convertible notes to support development and other strategic initiatives.

Participated · Equity · Jan 2021

Paycor provides cloud-based payroll, recruiting, HR and human capital management (HCM) software with a focus on modern, intuitive tools for business leaders. The company offers solutions across recruiting, onboarding, payroll, people development, analytics and dedicated HR support. Paycor says it partners with more than 40,000 medium and small-sized businesses and has been operating for 30 years. Leadership highlights recent investments in product, go-to-market and management to scale the business. The company announced commitments for $270 million in new investment to accelerate its strategy of serving customers with industry-leading technology and expertise. The financing is positioned to support continued growth and product development across its HCM platform.

Participated · Equity · Nov 2020

DataRobot offers an enterprise Augmented Intelligence platform that democratizes data science with end-to-end automation for building, deploying, and managing machine learning models. The platform combines software and implementation, training, and support services to help organizations deliver AI at scale and optimize performance over time. DataRobot says its platform is trusted by a third of the Fortune 50 and is used to drive predictive insights, improve forecasting, and reduce costs. The company announced the acquisition of Algorithmia to strengthen its MLOps capabilities and help customers move from experimental to applied AI. DataRobot plans to use new capital to fuel platform innovation and to expand its go-to-market team with hiring across North America, EMEA, and Asia Pacific/Japan. The company has global offices and longstanding backing from many institutional investors. DataRobot offers an enterprise AI platform that democratizes data science with end-to-end automation for building, deploying, and managing machine learning models. The platform is used by many Fortune 500 customers and has hosted the construction of more than two billion machine learning models on its cloud. DataRobot combines software with implementation, training, and support services to help organizations deliver AI at scale and continuously optimize performance. The company says it will use the new financing to accelerate rapid global growth. The announcement positions DataRobot as a leader in delivering trusted AI technology and enablement services across industries. The press release highlights strong market demand driven by data, cloud, and business intelligence trends and frames the company as poised to expand further. DataRobot provides a machine-learning platform aimed at analysts, developers and data scientists to accelerate building predictive models and delivering them as APIs. The company announced DataRobot MLOps, a tool to manage, monitor, and deploy machine-learning models across large organizations. It plans to use the new funding to continue building out its product line and pursue acquisitions where it makes sense. DataRobot reports triple-digit recurring revenue growth dating back to 2015 and says one billion models have been built on its platform. Customers named in the article include Humana, United Airlines, Harvard Business School and Deloitte. Founded in 2012 and based in Boston, the company has raised $431 million to date. DataRobot, founded in 2012 and based in Boston, offers an enterprise automated machine-learning platform that automates the process of building, training, evaluating, and deploying models. The platform incorporates a library of hundreds of open-source algorithms and runs model training and evaluation in parallel to deliver AI applications at scale. Over the last four years the company has processed over half a billion unique datasets and customers have built more than one billion models on the platform. DataRobot’s technology is used across industries and by organizations of all sizes to reduce costs, find new revenue opportunities, and identify threats. The company plans to expand its product portfolio, grow global operations, and develop its services offering. To date DataRobot has raised $225 million in total funding. DataRobot provides an enterprise-class platform that incorporates a library of hundreds of open-source machine-learning algorithms for data scientists of all skill levels. The platform automates the training and evaluation of predictive models across industries such as insurance, banking, healthcare, and fintech. Led by CEO and co-founder Jeremy Achin, the company serves enterprise customers and works with channel and technology partners including Cloudera, Alteryx, global systems integrators, analytics solution providers, and VARs. DataRobot said it will use the new funding to double the size of its research and development team and accelerate time-to-market for new features and capabilities. Additional plans include expanding its global presence and increasing support and expansion for global channel and technology partners. Financially, DataRobot closed a $54M first close of a Series C round, bringing total funding to $111M, with an additional undisclosed amount expected in a second close.